Semaglutide (NEJM, 2021) GI Adverse Events in SURPASS Trials (Patel et al., 2024) GI Tolerability in SURMOUNT Trials (Rubino et al., 2025) Drug-Induced Pancreatitis (PMC Review) Drug-Induced Kidney Problems (PMC Review) GLP-1 RA and Hair Loss: Systematic Review (PMC, 2025) Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
If muscle cramps persist despite adequate magnesium intake, low levels of other micronutrients (such as vitamin D, calcium, or potassium) may be the culprit
The numbers behind the BCBS reversal paint a clear picture of an industry struggling to absorb a cost explosion that had no precedent in modern pharmacy benefits
The Big Three Locations Abdomen
Gastroenterology , 117:942952
Safety Considerations at Higher Semaglutide Doses Higher semaglutide doses amplify GLP-1 signaling, which can intensify appetite suppression but may also increase the risk of gastrointestinal side effects like nausea, constipation, and dehydration